Form D · Biotechnology

Keliomics, Inc.

Portland, OR · CIK 0001949231

Offering snapshot reported Nov 30, 2023 · SEC filing

Reported sold
$2.28M
Offering amount: $7M
Investors reported
17
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 26, 2022
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$1.14M$2.28MOct 11, 2022: $250,000.00Oct 11, 2022Nov 30, 2023: $2,275,000.00Nov 30, 2023

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$250,000 → $2,275,000
  • Reported investors2 → 17

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 30, 2023Amendment$2,275,000$2,025,000vs Oct 11, 202217SEC filing
Oct 11, 2022Initial$250,000No comparison2SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-461343

Source: Form D, filed Nov 30, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jason Bourgeois Director, Executive
Frank Lau Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
4640 S. Macadam Avenue Suite 270
Portland, OR, 97239